PDF herunterladen
Semin Respir Crit Care Med 2010; 31(4): 474-484
DOI: 10.1055/s-0030-1262215
© Thieme Medical Publishers

Calcium and Vitamin D in Sarcoidosis: How to Assess and Manage

Robert R. Burke1 , 2 , Benjamin A. Rybicki3 , D. Sudhaker Rao4
  • 1Department of Internal Medicine, Wayne State University School of Medicine, Detroit, Michigan
  • 2Division of Pulmonary and Critical Care Medicine, Henry Ford Health System, Detroit, Michigan
  • 3Department of Research Epidemiology and Biostatistics, Henry Ford Hospital, Henry Ford Health System, Detroit, Michigan
  • 4Division of Endocrinology, Diabetes, and Bone and Mineral Disorders, Henry Ford Health System, Detroit, Michigan
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
27. Juli 2010 (online)

    Lizenzen und Reprints

ABSTRACT

The synthesis of vitamin D is altered by the granulomatous inflammation of sarcoidosis leading to increased production of 1, 25-dihydroxyvitamin D. Mounting evidence suggests that vitamin D is an immunomodulating hormone that inhibits both antigen presentation by cells of the innate immune system, and the cytokine release and proliferation of Th1 cells. These and other extraskeletal health benefits have led to an increase in vitamin D assessment and pharmacological supplementation in the general population. This review highlights the altered synthesis and general immunomodulating properties of vitamin D with a special emphasis on known interactions with sarcoidosis. In addition, the assessment of vitamin D nutritional status, its pharmacological supplementation, and the management of bone health in patients with sarcoidosis are reviewed.

KEYWORDS

Sarcoidosis - vitamin D - 1 - 25-dihydroxyvitamin D

REFERENCES

  • 1 Rao D S. Perspective on assessment of vitamin D nutrition.  J Clin Densitom. 1999;  2 457-464
    CrossrefPubMedGoogle Scholar
  • 2 Looker A C, Dawson-Hughes B, Calvo M S, Gunter E W, Sahyoun N R. Serum 25-hydroxyvitamin D status of adolescents and adults in two seasonal subpopulations from NHANES III.  Bone. 2002;  30 771-777
    CrossrefPubMedGoogle Scholar
  • 3 Zadshir A, Tareen N, Pan D, Norris K, Martins D. The prevalence of hypovitaminosis D among US adults: data from the NHANES III.  Ethn Dis. 2005;  15(4 Suppl 5) S5–97-101
    PubMedGoogle Scholar
  • 4 Norman A W, Bouillon R, Whiting S J, Vieth R, Lips P. 13th workshop consensus for vitamin D nutritional guidelines.  J Steroid Biochem Mol Biol. 2007;  103 204-205
    CrossrefPubMedGoogle Scholar
  • 5 Jones G, Strugnell S A, DeLuca H F. Current understanding of the molecular actions of vitamin D.  Physiol Rev. 1998;  78 1193-1231
    PubMedGoogle Scholar
  • 6 Baughman R P, Teirstein A S, Judson M A Case Control Etiologic Study of Sarcoidosis (ACCESS) research group et al. Clinical characteristics of patients in a case control study of sarcoidosis.  Am J Respir Crit Care Med. 2001;  164(10 Pt 1) 1885-1889
    CrossrefPubMedGoogle Scholar
  • 7 Meyrier A, Valeyre D, Bouillon R, Paillard F, Battesti J P, Georges R. Different mechanisms of hypercalciuria in sarcoidosis: correlations with disease extension and activity.  Ann N Y Acad Sci. 1986;  465 575-586
    CrossrefPubMedGoogle Scholar
  • 8 Adams J S, Gacad M A, Anders A, Endres D B, Sharma O P. Biochemical indicators of disordered vitamin D and calcium homeostasis in sarcoidosis.  Sarcoidosis. 1986;  3 1-6
    PubMedGoogle Scholar
  • 9 DeLuca H F, Schnoes H K. Metabolism and mechanism of action of vitamin D.  Annu Rev Biochem. 1976;  45 631-666
    CrossrefPubMedGoogle Scholar
  • 10 Provvedini D M, Tsoukas C D, Deftos L J, Manolagas S C. 1,25-dihydroxyvitamin D3 receptors in human leukocytes.  Science. 1983;  221 1181-1183
    CrossrefPubMedGoogle Scholar
  • 11 Bhalla A K, Amento E P, Clemens T L, Holick M F, Krane S M. Specific high-affinity receptors for 1,25-dihydroxyvitamin D3 in human peripheral blood mononuclear cells: presence in monocytes and induction in T lymphocytes following activation.  J Clin Endocrinol Metab. 1983;  57 1308-1310
    CrossrefPubMedGoogle Scholar
  • 12 Veldman C M, Cantorna M T, DeLuca H F. Expression of 1,25-dihydroxyvitamin D(3) receptor in the immune system.  Arch Biochem Biophys. 2000;  374 334-338
    CrossrefPubMedGoogle Scholar
  • 13 Niimi T, Tomita H, Sato S et al.. Vitamin D receptor gene polymorphism and calcium metabolism in sarcoidosis patients.  Sarcoidosis Vasc Diffuse Lung Dis. 2000;  17 266-269
    PubMedGoogle Scholar
  • 14 Niimi T, Tomita H, Sato S et al.. Vitamin D receptor gene polymorphism in patients with sarcoidosis.  Am J Respir Crit Care Med. 1999;  160 1107-1109
    CrossrefPubMedGoogle Scholar
  • 15 Rybicki B A, Maliarik M J, Poisson L M, Iannuzzi M C. Sarcoidosis and granuloma genes: a family-based study in African-Americans.  Eur Respir J. 2004;  24 251-257
    CrossrefPubMedGoogle Scholar
  • 16 Bellamy R, Ruwende C, Corrah T et al.. Tuberculosis and chronic hepatitis B virus infection in Africans and variation in the vitamin D receptor gene.  J Infect Dis. 1999;  179 721-724
    CrossrefPubMedGoogle Scholar
  • 17 Roy S, Frodsham A, Saha B, Hazra S K, Mascie-Taylor C G, Hill A V. Association of vitamin D receptor genotype with leprosy type.  J Infect Dis. 1999;  179 187-191
    CrossrefPubMedGoogle Scholar
  • 18 Wilkinson R J, Llewelyn M, Toossi Z et al.. Influence of vitamin D deficiency and vitamin D receptor polymorphisms on tuberculosis among Gujarati Asians in west London: a case-control study.  Lancet. 2000;  355 618-621
    CrossrefPubMedGoogle Scholar
  • 19 Uitterlinden A G, Fang Y, Van Meurs J B, Pols H AP, Van Leeuwen J P. Genetics and biology of vitamin D receptor polymorphisms.  Gene. 2004;  338 143-156
    CrossrefPubMedGoogle Scholar
  • 20 Reichel H, Koeffler H P, Tobler A, Norman A W. 1 alpha,25-Dihydroxyvitamin D3 inhibits gamma-interferon synthesis by normal human peripheral blood lymphocytes.  Proc Natl Acad Sci U S A. 1987;  84 3385-3389
    CrossrefPubMedGoogle Scholar
  • 21 Gyetko M R, Hsu C H, Wilkinson C C, Patel S, Young E. Monocyte 1 alpha-hydroxylase regulation: induction by inflammatory cytokines and suppression by dexamethasone and uremia toxin.  J Leukoc Biol. 1993;  54 17-22
    PubMedGoogle Scholar
  • 22 Stoffels K, Overbergh L, Giulietti A, Verlinden L, Bouillon R, Mathieu C. Immune regulation of 25-hydroxyvitamin-D3-1alpha-hydroxylase in human monocytes.  J Bone Miner Res. 2006;  21 37-47
    CrossrefPubMedGoogle Scholar
  • 23 Rosenthal A M, Jones G, Kooh S W, Fraser D. 25-hydroxyvitamin D3 metabolism by isolated perfused rat kidney.  Am J Physiol. 1980;  239 E12-E20
    PubMedGoogle Scholar
  • 24 Overbergh L, Decallonne B, Valckx D et al.. Identification and immune regulation of 25-hydroxyvitamin D-1-alpha-hydroxylase in murine macrophages.  Clin Exp Immunol. 2000;  120 139-146
    CrossrefPubMedGoogle Scholar
  • 25 Dusso A S, Kamimura S, Gallieni M et al.. Gamma-interferon-induced resistance to 1,25-(OH)2 D3 in human monocytes and macrophages: a mechanism for the hypercalcemia of various granulomatoses.  J Clin Endocrinol Metab. 1997;  82 2222-2232
    CrossrefPubMedGoogle Scholar
  • 26 Marshall T G. Vitamin D discovery outpaces FDA decision making.  Bioessays. 2008;  30 173-182
    CrossrefPubMedGoogle Scholar
  • 27 Xu Y, Hashizume T, Shuhart M C et al.. Intestinal and hepatic CYP3A4 catalyze hydroxylation of 1alpha,25-dihydroxyvitamin D(3): implications for drug-induced osteomalacia.  Mol Pharmacol. 2006;  69 56-65
    PubMedGoogle Scholar
  • 28 Li T, Chen W, Chiang J Y. PXR induces CYP27A1 and regulates cholesterol metabolism in the intestine.  J Lipid Res. 2007;  48 373-384
    CrossrefPubMedGoogle Scholar
  • 29 Zhou C, Assem M, Tay J C et al.. Steroid and xenobiotic receptor and vitamin D receptor crosstalk mediates CYP24 expression and drug-induced osteomalacia.  J Clin Invest. 2006;  116 1703-1712
    CrossrefPubMedGoogle Scholar
  • 30 Blaney G P, Albert P J, Proal A D. Vitamin D metabolites as clinical markers in autoimmune and chronic disease.  Ann N Y Acad Sci. 2009;  1173 384-390
    CrossrefPubMedGoogle Scholar
  • 31 Merlino L A, Curtis J, Mikuls T R, Cerhan J R, Criswell L A, Saag K G. Iowa Women’s Health Study . Vitamin D intake is inversely associated with rheumatoid arthritis: results from the Iowa Women’s Health Study.  Arthritis Rheum. 2004;  50 72-77
    CrossrefPubMedGoogle Scholar
  • 32 Costenbader K H, Feskanich D, Holmes M, Karlson E W, Benito-Garcia E. Vitamin D intake and risks of systemic lupus erythematosus and rheumatoid arthritis in women.  Ann Rheum Dis. 2008;  67 530-535
    CrossrefPubMedGoogle Scholar
  • 33 Hyppönen E, Läärä E, Reunanen A, Järvelin M R, Virtanen S M. Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study.  Lancet. 2001;  358 1500-1503
    CrossrefPubMedGoogle Scholar
  • 34 Lemire J M, Ince A, Takashima M. 1,25-Dihydroxyvitamin D3 attenuates the expression of experimental murine lupus of MRL/l mice.  Autoimmunity. 1992;  12 143-148
    CrossrefPubMedGoogle Scholar
  • 35 Cantorna M T, Hayes C E, DeLuca H F. 1,25-Dihydroxycholecalciferol inhibits the progression of arthritis in murine models of human arthritis.  J Nutr. 1998;  128 68-72
    PubMedGoogle Scholar
  • 36 Mathieu C, Waer M, Laureys J, Rutgeerts O, Bouillon R. Prevention of autoimmune diabetes in NOD mice by 1,25 dihydroxyvitamin D3.  Diabetologia. 1994;  37 552-558
    CrossrefPubMedGoogle Scholar
  • 37 Cantorna M T, Munsick C, Bemiss C, Mahon B D. 1,25-Dihydroxycholecalciferol prevents and ameliorates symptoms of experimental murine inflammatory bowel disease.  J Nutr. 2000;  130 2648-2652
    PubMedGoogle Scholar
  • 38 Clohisy D R, Bar-Shavit Z, Chappel J C, Teitelbaum S L. 1,25-Dihydroxyvitamin D3 modulates bone marrow macrophage precursor proliferation and differentiation: up-regulation of the mannose receptor.  J Biol Chem. 1987;  262 15922-15929
    PubMedGoogle Scholar
  • 39 Amento E P, Bhalla A K, Kurnick J T et al.. 1 alpha,25-dihydroxyvitamin D3 induces maturation of the human monocyte cell line U937, and, in association with a factor from human T lymphocytes, augments production of the monokine, mononuclear cell factor.  J Clin Invest. 1984;  73 731-739
    CrossrefPubMedGoogle Scholar
  • 40 Zuckerman S H, Schreiber R D. Up-regulation of gamma interferon receptors on the human monocytic cell line U937 by 1,25-dihydroxyvitamin D3 and granulocyte-macrophage colony stimulating factor.  J Leukoc Biol. 1988;  44 187-191
    PubMedGoogle Scholar
  • 41 Liu P T, Stenger S, Li H et al.. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response.  Science. 2006;  311 1770-1773
    CrossrefPubMedGoogle Scholar
  • 42 Ohta M, Okabe T, Ozawa K, Urabe A, Takaku F. In vitro formation of macrophage-epithelioid cells and multinucleated giant cells by 1 alpha,25-dihydroxyvitamin D3 from human circulating monocytes.  Ann N Y Acad Sci. 1986;  465 211-220
    CrossrefPubMedGoogle Scholar
  • 43 Penna G, Adorini L. 1 Alpha,25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation.  J Immunol. 2000;  164 2405-2411
    PubMedGoogle Scholar
  • 44 Piemonti L, Monti P, Sironi M et al.. Vitamin D3 affects differentiation, maturation, and function of human monocyte-derived dendritic cells.  J Immunol. 2000;  164 4443-4451
    CrossrefPubMedGoogle Scholar
  • 45 Gregori S, Casorati M, Amuchastegui S, Smiroldo S, Davalli A M, Adorini L. Regulatory T cells induced by 1 alpha,25-dihydroxyvitamin D3 and mycophenolate mofetil treatment mediate transplantation tolerance.  J Immunol. 2001;  167 1945-1953
    PubMedGoogle Scholar
  • 46 Lemire J M, Adams J S, Kermani-Arab V, Bakke A C, Sakai R, Jordan S C. 1,25-Dihydroxyvitamin D3 suppresses human T helper/inducer lymphocyte activity in vitro.  J Immunol. 1985;  134 3032-3035
    PubMedGoogle Scholar
  • 47 Provvedini D M, Manolagas S C. 1 Alpha,25-dihydroxyvitamin D3 receptor distribution and effects in subpopulations of normal human T lymphocytes.  J Clin Endocrinol Metab. 1989;  68 774-779
    CrossrefPubMedGoogle Scholar
  • 48 Griffin M D, Lutz W H, Phan V A, Bachman L A, McKean D J, Kumar R. Potent inhibition of dendritic cell differentiation and maturation by vitamin D analogs.  Biochem Biophys Res Commun. 2000;  270 701-708
    CrossrefPubMedGoogle Scholar
  • 49 D’Ambrosio D, Cippitelli M, Cocciolo M G et al.. Inhibition of IL-12 production by 1,25-dihydroxyvitamin D3: involvement of NF-kappaB downregulation in transcriptional repression of the p40 gene.  J Clin Invest. 1998;  101 252-262
    CrossrefPubMedGoogle Scholar
  • 50 Matsui T, Takahashi R, Nakao Y et al.. 1,25-Dihydroxyvitamin D3-regulated expression of genes involved in human T-lymphocyte proliferation and differentiation.  Cancer Res. 1986;  46 5827-5831
    PubMedGoogle Scholar
  • 51 Gorman S, Kuritzky L A, Judge M A et al.. Topically applied 1,25-dihydroxyvitamin D3 enhances the suppressive activity of CD4+ CD25+ cells in the draining lymph nodes.  J Immunol. 2007;  179 6273-6283
    PubMedGoogle Scholar
  • 52 Barrat F J, Cua D J, Boonstra A et al.. In vitro generation of interleukin 10-producing regulatory CD4(+) T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)- and Th2-inducing cytokines.  J Exp Med. 2002;  195 603-616
    CrossrefPubMedGoogle Scholar
  • 53 Hansdottir S, Monick M M, Hinde S L, Lovan N, Look D C, Hunninghake G W. Respiratory epithelial cells convert inactive vitamin D to its active form: potential effects on host defense.  J Immunol. 2008;  181 7090-7099
    CrossrefPubMedGoogle Scholar
  • 54 Yim S, Dhawan P, Ragunath C, Christakos S, Diamond G. Induction of cathelicidin in normal and CF bronchial epithelial cells by 1,25-dihydroxyvitamin D(3).  J Cyst Fibros. 2007;  6 403-410
    CrossrefPubMedGoogle Scholar
  • 55 Morimoto T, Azuma A, Abe S et al.. Epidemiology of sarcoidosis in Japan.  Eur Respir J. 2008;  31 372-379
    CrossrefPubMedGoogle Scholar
  • 56 Rossman M D, Thompson B, Frederick M ACCESS Group et al. HLA and environmental interactions in sarcoidosis.  Sarcoidosis Vasc Diffuse Lung Dis. 2008;  25 125-132
    PubMedGoogle Scholar
  • 57 Mahévas M, Lescure F X, Boffa J J et al.. Renal sarcoidosis: clinical, laboratory, and histologic presentation and outcome in 47 patients.  Medicine (Baltimore). 2009;  88 98-106
    CrossrefPubMedGoogle Scholar
  • 58 Adams J S, Sharma O P, Gacad M A, Singer F R. Metabolism of 25-hydroxyvitamin D3 by cultured pulmonary alveolar macrophages in sarcoidosis.  J Clin Invest. 1983;  72 1856-1860
    CrossrefPubMedGoogle Scholar
  • 59 Lafferty F W. Differential diagnosis of hypercalcemia.  J Bone Miner Res. 1991;  6(Suppl 2) S51-59 discussion S61
    CrossrefPubMedGoogle Scholar
  • 60 Ding E L, Mehta S, Fawzi W W, Giovannucci E L. Interaction of estrogen therapy with calcium and vitamin D supplementation on colorectal cancer risk: reanalysis of Women’s Health Initiative randomized trial.  Int J Cancer. 2008;  122 1690-1694
    CrossrefPubMedGoogle Scholar
  • 61 Chlebowski R T, Johnson K C, Kooperberg C Women’s Health Initiative Investigators et al. Calcium plus vitamin D supplementation and the risk of breast cancer.  J Natl Cancer Inst. 2008;  100 1581-1591
    CrossrefPubMedGoogle Scholar
  • 62 LaCroix A Z, Kotchen J, Anderson G et al.. Calcium plus vitamin D supplementation and mortality in postmenopausal women: the Women’s Health Initiative calcium-vitamin D randomized controlled trial.  J Gerontol A Biol Sci Med Sci. 2009;  64 559-567
    PubMedGoogle Scholar
  • 63 Lappe J M, Travers-Gustafson D, Davies K M, Recker R R, Heaney R P. Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial.  Am J Clin Nutr. 2007;  85 1586-1591
    PubMedGoogle Scholar
  • 64 Wactawski-Wende J, Kotchen J M, Anderson G L Women’s Health Initiative Investigators et al. Calcium plus vitamin D supplementation and the risk of colorectal cancer.  N Engl J Med. 2006;  354 684-696
    CrossrefPubMedGoogle Scholar
  • 65 Montemurro L, Fraioli P, Rizzato G. Bone loss in untreated longstanding sarcoidosis.  Sarcoidosis. 1991;  8 29-34
    PubMedGoogle Scholar
  • 66 van Staa T P, Leufkens H G, Cooper C, Leufkens H GM, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis.  Osteoporos Int. 2002;  13 777-787
    CrossrefPubMedGoogle Scholar
  • 67 van Staa T P, Geusens P, Pols H AP, de Laet C, Leufkens H GM, Cooper C. A simple score for estimating the long-term risk of fracture in patients using oral glucocorticoids.  QJM. 2005;  98 191-198
    CrossrefPubMedGoogle Scholar
  • 68 Rizzato G, Tosi G, Mella C, Montemurro L, Zanni D, Sisti S. Prednisone-induced bone loss in sarcoidosis: a risk especially frequent in postmenopausal women.  Sarcoidosis. 1988;  5 93-98
    PubMedGoogle Scholar
  • 69 Montemurro L, Fraioli P, Riboldi A, Delpiano S, Zanni D, Rizzato G. Bone loss in prednisone treated sarcoidosis: a two-year follow-up.  Ann Ital Med Int. 1990;  5(3 Pt 1) 164-168
    PubMedGoogle Scholar
  • 70 Heijckmann A C, Huijberts M S, De Vries J et al.. Bone turnover and hip bone mineral density in patients with sarcoidosis.  Sarcoidosis Vasc Diffuse Lung Dis. 2007;  24 51-58
    PubMedGoogle Scholar
  • 71 Rizzato G, Fraioli P. Natural and corticosteroid-induced osteoporosis in sarcoidosis: prevention, treatment, follow up and reversibility.  Sarcoidosis. 1990;  7 89-92
    PubMedGoogle Scholar
  • 72 Rizzato G, Tosi G, Schiraldi G, Montemurro L, Zanni D, Sisti S. Bone protection with salmon calcitonin (sCT) in the long-term steroid therapy of chronic sarcoidosis.  Sarcoidosis. 1988;  5 99-103
    PubMedGoogle Scholar
  • 73 Montemurro L, Schiraldi G, Fraioli P, Tosi G, Riboldi A, Rizzato G. Prevention of corticosteroid-induced osteoporosis with salmon calcitonin in sarcoid patients.  Calcif Tissue Int. 1991;  49 71-76
    CrossrefPubMedGoogle Scholar
  • 74 Cummings S R, Karpf D B, Harris F et al.. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs.  Am J Med. 2002;  112 281-289
    CrossrefPubMedGoogle Scholar
  • 75 Karpf D B, Shapiro D R, Seeman E Alendronate Osteoporosis Treatment Study Groups et al. Prevention of nonvertebral fractures by alendronate: a meta-analysis.  JAMA. 1997;  277 1159-1164
    CrossrefPubMedGoogle Scholar
  • 76 Gonnelli S, Rottoli P, Cepollaro C et al.. Prevention of corticosteroid-induced osteoporosis with alendronate in sarcoid patients.  Calcif Tissue Int. 1997;  61 382-385
    CrossrefPubMedGoogle Scholar
  • 77 Qaseem A, Snow V, Shekelle P, Hopkins Jr R J, Forciea M A, Owens D K. Clinical Efficacy Assessment Subcommittee of the American College of Physicians . Pharmacologic treatment of low bone density or osteoporosis to prevent fractures: a clinical practice guideline from the American College of Physicians.  Ann Intern Med. 2008;  149 404-415
    PubMedGoogle Scholar
  • 78 American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis . Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update.  Arthritis Rheum. 2001;  44 1496-1503
    CrossrefPubMedGoogle Scholar
  • 79 Bischoff-Ferrari H A, Willett W C, Wong J B, Giovannucci E, Dietrich T, Dawson-Hughes B. Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials.  JAMA. 2005;  293 2257-2264
    CrossrefPubMedGoogle Scholar
  • 80 Infante J R, Pacheco C, Torres-Avisbal M, Vallejo J A, González F M, Latre J M. Pulmonary activity in sarcoidosis: 67Ga uptake quantification and plasma determination of 1,25-dihydroxyvitamin D [in Spanish].  Rev Esp Med Nucl. 2002;  21 275-280
    PubMedGoogle Scholar
  • 81 Kavathia D, Buckley J D, Rao D, Rybicki B, Burke R. Elevated 1, 25-dihydroxyvitamin D levels are associated with protracted treatment in sarcoidosis.  Respir Med. 2010;  104 564-570
    CrossrefPubMedGoogle Scholar
  • 82 Prasse A, Katic C, Germann M, Buchwald A, Zissel G, Müller-Quernheim J. Phenotyping sarcoidosis from a pulmonary perspective.  Am J Respir Crit Care Med. 2008;  177 330-336
    CrossrefPubMedGoogle Scholar
  • 83 Adams J S, Gacad M A, Diz M M, Nadler J L. A role for endogenous arachidonate metabolites in the regulated expression of the 25-hydroxyvitamin D-1-hydroxylation reaction in cultured alveolar macrophages from patients with sarcoidosis.  J Clin Endocrinol Metab. 1990;  70 595-600
    CrossrefPubMedGoogle Scholar
  • 84 Reichel H, Koeffler H P, Barbers R, Norman A W. Regulation of 1,25-dihydroxyvitamin D3 production by cultured alveolar macrophages from normal human donors and from patients with pulmonary sarcoidosis.  J Clin Endocrinol Metab. 1987;  65 1201-1209
    CrossrefPubMedGoogle Scholar
  • 85 Rigby W F, Denome S, Fanger M W. Regulation of lymphokine production and human T lymphocyte activation by 1,25-dihydroxyvitamin D3. Specific inhibition at the level of messenger RNA.  J Clin Invest. 1987;  79 1659-1664
    CrossrefPubMedGoogle Scholar

Robert R BurkeM.D. 

Division of Pulmonary and Critical Care Medicine

K17, Henry Ford Hospital, 2799 W. Grand Blvd., Detroit, MI 48202

eMail: Rburke1@hfhs.org

      >